keyword
MENU ▼
Read by QxMD icon Read
search

ingenol mebutate

keyword
https://www.readbyqxmd.com/read/29115209/exploring-the-use-of-ingenol-mebutate-to-prevent-non-melanoma-skin-cancer
#1
Andrés Már Erlendsson
Non-melanoma skin cancer is the most frequently occurring cancer in Caucasians today. Incidence rates in Europe have increased steadily since the 1960s and more than tripled over the last 50 years. Despite primary preventative efforts, incidences of non-melanoma skin cancer continue to rise and development of effective chemopreventative strategies is needed. In 2013, ingenol mebutate was approved in Denmark as a new topical drug for field-directed treatment for actinic keratoses. Ingenol mebutate has a dual mechanism of action, causing initial cell death, followed by an immune activation...
November 2017: Danish Medical Journal
https://www.readbyqxmd.com/read/29104717/ingenol-mebutate-for-the-treatment-of-intraepidermal-squamous-cell-carcinoma
#2
Efstathios Rallis, Angeliki Liakopoulou, Constantinos Christodoulopoulos
No abstract text is available yet for this article.
July 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29067277/factors-influencing-response-to-ingenol-mebutate-therapy-for-actinic-keratosis-of-face-and-scalp
#3
Nevena Skroza, Ilaria Proietti, Nicoletta Bernardini, Veronica Balduzzi, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Sara Zuber, Giuseppe La Torre, Concetta Potenza
AIM: To determine factors independently influencing response to ingenol mebutate therapy and assess efficacy on clinical setting of non-hypertrophic non-hyperkeratotic actinic keratosis (AK). METHODS: Consecutive patients affected by non-hypertrophic non-hyperkeratotic AKs of the face or scalp were enrolled to receive ingenol mebutate 0.015% gel on a selected skin area of 25 cm(2) for 3 consecutive days. Local skin reactions were calculated at each follow up visit using a validated composite score...
October 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29030864/phase-iv-head-to-head-randomised-controlled-trial-comparing-ingenol-mebutate-0-015-gel-with-diclofenac-sodium-3-gel-for-the-treatment-of-actinic-keratosis-on-the-face-or-scalp
#4
E Stockfleth, C A Harwood, C Serra Guillén, T Larsson, M L Østerdal, T Skov
BACKGROUND: Ingenol mebutate (IngMeb) and diclofenac sodium (DS) are approved treatments for actinic keratosis (AK). OBJECTIVES: Compare efficacy and safety of IngMeb 0.015% gel with DS 3% gel. METHODS: Patients with 4-8 visible, discrete AK lesions on face/scalp in a 25 cm(2) contiguous area of skin were randomised 1:1 to IngMeb once-daily for 3 consecutive days, or DS twice-daily for 90 days, following label instruction. Patients presenting with AK lesions at Week 8 following IngMeb were offered a second IngMeb course...
October 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29024025/an-exploratory-prospective-open-label-trial-of-ingenol-mebutate-gel-0-05-for-the-treatment-of-external-anogenital-warts
#5
H K Larsen, C A Banzhaf, S F Thomsen, M Gormsen, R E Schopf, M Haedersdal
BACKGROUND: Anogenital warts (AGW) can cause physical discomfort and decreased quality of life. Recent case reports suggest that ingenol mebutate gel might be an effective treatment of AGW. OBJECTIVE: To explore primarily the safety, and secondarily the efficacy of ingenol mebutate gel 0.05% in patients with AGW. METHODS: This was an exploratory, open-label, 1-arm trial of ingenol mebutate gel 0.05% administered up to 3 times to patients with AGW...
October 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28979661/a-prospective-pilot-clinical-trial-to-evaluate-the-efficacy-and-safety-of-topical-therapy-with-ingenol-mebutate-gel-0-015-for-actinic-keratosis-on-an-expanded-area-of-the-chest
#6
Douglas C Wu, Isabella Guiha, Mitchel P Goldman
BACKGROUND: Ingenol mebutate gel 0.05% once daily for two consecutive days provides high clearance rates for actinic keratosis on a 25cm(2) area of the chest. However, it may cause intense local skin responses. OBJECTIVE: The objective of this study was to determine whether a lower dose of ingenol mebutate gel 0.015% could clear actinic keratosis on the chest with acceptable tolerability and a possible beneficial effect on photodamage and cosmesis. DESIGN: This was a noncomparative, open-label study (NCT02446223)...
August 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/28956675/ingenol-mebutate-for-the-treatment-of-actinic-keratosis-effectiveness-and-safety-in-246-patients-treated-in-real-life-clinical-practice
#7
Rosa Ortega Del Olmo, Rafael Salido-Vallejo
INTRODUCTION: The aim of the study was to evaluate the results on effectiveness and safety of topical treatment for Actinic Keratosis (AK) with Ingenol Mebutate Gel (IMG) in real-life conditions and to perform an analysis of the factors that may influence the treatment outcomes. MATERIALS AND METHODS: Retrospective study of patients with non-hyperkeratotic AK lesions prescribed with IMG in Spain according to clinical practice. Dermatologists reported the characteristics of patients and AK at baseline, and the findings observed up to 60 days after treatment...
September 28, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28895376/erosive-pustular-dermatosis-of-the-scalp-induced-by-ingenol-mebutate
#8
Lucia Brambilla, Athanasia Tourlaki, Gianluca Nazzaro
No abstract text is available yet for this article.
September 8, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28859143/the-effect-of-wool-hydrolysates-on-squamous-cell-carcinoma-cells-in-vitro-possible-implications-for-cancer-treatment
#9
Tatsiana Damps, Anna Katarzyna Laskowska, Tomasz Kowalkowski, Monika Prokopowicz, Anna Katarzyna Puszko, Piotr Sosnowski, Joanna Czuwara, Marek Konop, Krzysztof Różycki, Joanna Karolina Borkowska, Aleksandra Misicka, Lidia Rudnicka
Squamous cell carcinoma of the skin is the second most common cutaneous malignancy. Despite various available treatment methods and advances in noninvasive diagnostic techniques, the incidence of metastatic cutaneous squamous cell carcinoma is rising. Deficiency in effective preventive or treatment methods of transformed keratinocytes leads to necessity of searching for new anticancer agents. The present study aims to evaluate the possibility of using wool hydrolysates as such agents. Commercially available compounds such as 5-fluorouracil, ingenol mebutate, diclofenac sodium salt were also used in this study...
2017: PloS One
https://www.readbyqxmd.com/read/28858927/clinical-and-histologic-evaluation-of-ingenol-mebutate-0-015-gel-for-the-cosmetic-improvement-of-photoaged-skin
#10
Marc Z Handler, Bradley S Bloom, David J Goldberg
BACKGROUND: No studies have examined the use of topical ingenol mebutate for improvement of photoaged skin. OBJECTIVE: To evaluate clinical results of ingenol mebutate gel applied to photoaged skin and to quantify improvement at 7, 30, and 60 days after application. MATERIALS AND METHODS: Twenty-five subjects were enrolled in the study. Picato (ingenol mebutate) (LEO Pharma, Parsippany, NJ) gel was applied to an area with a known actinic keratosis daily for 3 days...
August 30, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28761314/a-case-of-bowen-s-disease-successfully-treated-with-ingenol-mebutate-gel
#11
Je-Byeong Chae, Jung-Tae Park, Bo-Ri Kim, Chang-Hun Huh, Kyoung-Chan Park, Jung-Won Shin
No abstract text is available yet for this article.
August 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28685901/erosive-pustular-dermatosis-of-the-scalp-following-topical-ingenol-mebutate-for-actinic-keratoses
#12
LETTER
Mario Vaccaro, Francesco Borgia, Lorenzo Gasco, Serafinella P Cannavò
No abstract text is available yet for this article.
September 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28661992/treatment-patterns-outcomes-and-patient-satisfaction-of-primary-epidermally-limited-nonmelanoma-skin-cancer
#13
Benjamin A Drew, Pritesh S Karia, Ariana N Mora, Christine A Liang, Chrysalyne D Schmults
BACKGROUND: Epidermally limited nonmelanoma skin cancer (ELNMSC) (superficial basal cell carcinoma [SBCC] and squamous cell carcinoma in situ [SCCIS]) is common. Data on outcomes and patient satisfaction are lacking. OBJECTIVE: To examine treatment efficacy and satisfaction in ELNMSC patients. PATIENTS AND METHODS: Retrospective cohort study of adults with primary SBCC or SCCIS. A 25% random subset completed a satisfaction questionnaire. RESULTS: Five hundred and fifty patients with 227 SBCC and 451 SCCIS were included; 329 tumors (49%) were treated with Mohs micrographic surgery (MMS) and 349 (51%) with non-MMS (imiquimod [n = 26], 5% 5-fluorouracil [n = 234], ingenol mebutate [n = 32], or cryotherapy [n = 57])...
June 28, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28658998/patient-reported-outcomes-in-topical-field-treatment-of-actinic-keratosis-in-swedish-and-danish-patients
#14
Hanna Norrlid, Jenny M Norlin, Heidi Holmstrup, Irena Malmberg, Karin Sartorius, Henrik Thormann, Gregor B E Jemec, Gunnel Ragnarson Tennvall
Topical treatments in dermatology can be long, complex and lead to nonadherence and nonpersistence to prescribed treatment. Clinical efficacy observed in randomized clinical trials (RCT) may therefore be reduced in real-world clinical practice. The objective of this study was to analyze patient-reported treatment adherence, treatment satisfaction and health-related quality of life (HRQoL) with topical treatments of actinic keratosis (AK) in routine clinical practice in Denmark and Sweden. Adult patients prescribed field-directed topical AK treatments with diclofenac gel, imiquimod or ingenol mebutate per routine clinical practice were eligible for the observational RAPID-ACT study...
June 29, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28628679/safety-and-efficacy-of-escalating-doses-of-ingenol-mebutate-for-field-treatment-of-actinic-keratosis-on-the-full-face-full-balding-scalp-or-chest
#15
C William Hanke, Brian Berman, Neil Swanson, David M Pariser, Jonathan S Weiss, Michael Bukhalo, Torsten Skov, John Villumsen, Daniel Siegel
<p>Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2.</p> <p>Objective: The study sought to determine the maximum tolerated dose (MTD), efficacy, and tolerability of IngMeb applied to AK on a contiguous area less than equal to 250 cm2.</p> <p>Methods: Part 1 determined the MTD of IngMeb at 7 concentrations for 2 or 3 days. Part 2 assessed efficacy and tolerability at the MTD and one dose lower for 2 or 3 days vs vehicle...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28628678/assessment-of-efficacy-and-irritation-of-ingenol-mebutate-gel-0-015-used-with-or-without-dimethicone-lotion-for-treatment-of-actinic-keratosis-on-the-face
#16
Shelbi C Jim On, Peter W Hashim, John K Nia, Mark G Lebwohl
<p>Background: Ingenol mebutate gel 0.015% provides high clearance rates for actinic keratosis (AK) on the face and scalp but causes transient local skin responses (LSRs).</p> <p>Objective: This study sought to determine whether the application of 1% dimethicone would decrease ingenol mebutate-associated LSRs and/or affect efficacy during the treatment of multiple AKs on the face.</p> <p>Methods: Ingenol mebutate gel 0.015% was applied for 3 days to two 25 cm2 areas, each containing 3 to 8 AKs on the face of each subject, followed by application of 1% dimethicone lotion in an investigator-blinded manner to one randomly selected AK-containing area until LSRs were no longer present...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28621441/exuberant-granulation-tissue-successfully-treated-with-ingenol-mebutate-two-cases-report
#17
LETTER
María Encarnación Gómez Sánchez, María Luisa Martínez Martínez, Tomás Toledo Pastrana, Almudena Nuño González, Jose Manuel Azaña Defez, Jose Luis Agudo Mena
No abstract text is available yet for this article.
July 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28619577/ingenol-mebutate-for-the-management-of-genital-warts-in-sensitive-anatomic-locations
#18
Stephan Alexander Braun, Peter Arne Gerber
No abstract text is available yet for this article.
July 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28580871/pharmacoeconomic-evaluations-in-the-treatment-of-actinic-keratoses
#19
Keith Tolley, Giuseppe Argenziano, Pier Giacomo Calzavara-Pinton, Thomas Larsson, Lasse Ryttig
Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac...
June 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28579816/tattoo-removal-with-ingenol-mebutate
#20
Sarah-Jane Cozzi, Thuy T Le, Steven M Ogbourne, Cini James, Andreas Suhrbier
An increasing number of people are getting tattoos; however, many regret the decision and seek their removal. Lasers are currently the most commonly used method for tattoo removal; however, treatment can be lengthy, costly, and sometimes ineffective, especially for certain colors. Ingenol mebutate is a licensed topical treatment for actinic keratoses. Here, we demonstrate that two applications of 0.1% ingenol mebutate can efficiently and consistently remove 2-week-old tattoos from SKH/hr hairless mice. Treatment was associated with relocation of tattoo microspheres from the dermis into the posttreatment eschar...
2017: Clinical, Cosmetic and Investigational Dermatology
keyword
keyword
51369
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"